Genentech同意购买Regor乳癌CDK抑制器, Genentech agrees to purchase Regor's breast cancer CDK inhibitors for $850M upfront, with potential milestones, in a Q4 2024 deal.

作为Roche集团一部分的Genentech公司已同意购买Regor制药公司下一代CDK乳癌抑制剂,预付8.5亿美元,并可能与未来里程碑挂钩的额外付款。 Genentech, part of the Roche Group, has agreed to purchase Regor Pharmaceuticals' next-generation CDK inhibitors for breast cancer for $850 million upfront, with potential additional payments tied to future milestones. Genentech将处理临床发展、制造和商业化。 Genentech will handle clinical development, manufacturing, and commercialization. 收购预计将在2024年第四季度完成,而Regor将继续管理其目前的第一阶段试验和其他瘤资产. The acquisition is expected to finalize in Q4 2024, while Regor will continue managing its current Phase 1 trials and other oncology assets.